

Special Issue

Sarcoma: Clinical Trials and Management

Message from the Guest Editors

Sarcoma represents a heterogenous collection of mesenchymal neoplasms originating in the soft tissue and bone. There are over 50 different histologic subtypes of sarcoma, and these differ by differentiation, clinical behavior, genetics, age of occurrence, and response to different therapies. The optimal treatment of sarcoma can vary significantly between different histologic subtypes. Over the past decade, several innovative therapies have revolutionized the field of oncology and have challenged conventional notions of cancer treatment. New molecular targets have been identified, and immunotherapy has dramatically changed the treatment landscape for multiple malignancies, including several sarcoma subtypes. In this present Special Issue, we are particularly interested in manuscripts reporting original findings or updated literature reviews concerning the treatment of sarcoma. We seek to highlight innovative strategies that may lead to improvements in the management of bone and soft tissue sarcomas.

Guest Editors

Prof. Dr. Mohammed M. Milhem

Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA

Dr. John Rieth

Holden Comprehensive Cancer Center, University of Iowa Hospitals & Clinics, 200 Hawkins Drive, Iowa City, IA 52242, USA

Deadline for manuscript submissions

closed (30 November 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/194660

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)